Core Viewpoint - The CarMax class action lawsuit alleges that the company and its executives misrepresented growth prospects, leading to significant stock price declines following disappointing financial results and executive termination announcements [3][4][5]. Group 1: Class Action Details - The class action lawsuit is titled Cap v. CarMax, Inc., and it involves purchasers of CarMax securities from June 20, 2025, to November 5, 2025, with a deadline of January 2, 2026, for lead plaintiff applications [1]. - The lawsuit claims that CarMax overstated its growth prospects, attributing earlier fiscal year growth to temporary factors related to customer behavior influenced by tariff speculation [3]. Group 2: Financial Performance - On September 25, 2025, CarMax reported a 5.4% decrease in retail unit sales and a 6.3% decrease in comparable store unit sales, with net earnings per diluted share dropping to $0.64 from $0.85 the previous year, resulting in a 20% drop in share price [4]. - Following the termination of CEO William D. Nash on November 4, 2025, and the expectation of weak third-quarter sales, CarMax shares fell more than 24% [5]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased CarMax securities during the class period to seek lead plaintiff status, representing the interests of the class [6].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited and certain officers for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Class Action Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Telix securities between February 21, 2025, and August 28, 2025 [2]. - The complaint alleges that the defendants made false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects [3]. Group 2: Next Steps and Participation - Investors who suffered losses in Telix have until January 9, 2026, to request to be appointed as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate, sonelokimab (SLK), which was claimed to be superior to existing therapies but reportedly lacks demonstrated clinical advantages [3][4]. Company Overview - MoonLake Immunotherapeutics is a biopharmaceutical company based in Zug, Switzerland, focusing on therapies for inflammatory diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased MoonLake shares from March 10, 2024, to September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint alleges that MoonLake failed to disclose that SLK targets the same molecules as the FDA-approved drug BIMZELX, undermining claims of its clinical superiority [3]. Clinical Trial Outcome - On September 28, 2025, MoonLake disclosed that SLK did not achieve efficacy comparable to BIMZELX in Phase 3 clinical trials, leading to a significant stock price drop of $55.75 per share, nearly 90% in one trading day [4].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential violations of federal securities laws by Soleno Therapeutics, Inc. and its officers regarding misleading statements and undisclosed material information to investors [1][2]. Group 1: Investigation Details - The investigation focuses on whether Soleno's communications accurately represented the commercial progress and safety profile of VYKAT™ XR after its FDA approval [2]. - Following the FDA clearance in September 2025, Soleno claimed that the product rollout was exceeding internal expectations [2]. Group 2: Earnings Call Insights - During the third-quarter earnings call on November 4, 2025, Soleno acknowledged challenges in the launch of VYKAT™ XR, including a slowdown in new treatment initiations and an increase in therapy discontinuations due to non-serious adverse events [3]. - Management indicated that external commentary earlier in the year had negatively impacted the launch trajectory [3]. Group 3: Short Seller Report - On August 15, 2025, Scorpion Capital released a report raising concerns about VYKAT™ XR, questioning its safety profile, demand sustainability, and the concentration of early prescribing activity [4]. - The report criticized Soleno's business model for being overly reliant on a single product with impending intellectual property expiration and suggested that certain clinical research needed further examination [4]. Group 4: Stock Price Volatility - Following the Scorpion report, Soleno's stock price experienced significant volatility, declining nearly 40% from August 14, 2025, to November 5, 2025 [5].

Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include those who purchased CarMax securities between June 20, 2025, and November 5, 2025 [1] Allegations of Misconduct - The complaint alleges that Defendants made false and/or misleading statements regarding CarMax's growth prospects, claiming that earlier growth was a temporary benefit due to customer speculation about tariffs [3] - It is asserted that the positive statements made by Defendants about the company's business and operations were materially misleading and lacked a reasonable basis [3] Lead Plaintiff Process - CarMax investors can seek to be appointed as a lead plaintiff representative of the class by January 2, 2026, or may choose to remain an absent class member [4] - The lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5]

Core Viewpoint - A class action securities lawsuit has been filed against James Hardie Industries plc, alleging securities fraud that affected shareholders between May 20, 2025, and August 18, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for shareholders who were adversely affected by alleged securities fraud during the specified period [2]. - The complaint claims that the defendants made false statements and concealed critical facts regarding the North America segment of James Hardie, including deteriorating consumer demand and growth [3]. - It is alleged that overstocking was the main driver of growth in the North America segment, rather than genuine consumer demand, leading to excessive inventory at distributors [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the relevant timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [3]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [3]. Group 2: Recovery Information - Shareholders who experienced losses in MoonLake stock during the specified timeframe are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [4][6]. - Interested parties can find more information and submit claims through the provided link [4][6]. Group 3: Legal Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Points - A class action securities lawsuit has been filed against aTyr Pharma, Inc. to recover losses for shareholders affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [2][3] - The lawsuit claims that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper off steroid usage [3][4] - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4][5] Company Impact - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in just one day [5] - The company plans to engage with the FDA to determine the next steps after the disappointing study results [4] Legal Context - Shareholders who suffered losses during the relevant time frame are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [6] - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this case, highlighting their extensive experience and success in similar cases [7]

New York, New York--(Newsfile Corp. - November 11, 2025) - If you suffered a loss on your CarMax, Inc. (NYSE: KMX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/carmax-inc-lawsuit-submission-form?prid=176750&wire=5&utm_campaign=21or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.THE LAWSUIT: A clas ...

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. to recover losses incurred by shareholders due to alleged securities fraud between December 15, 2021, and September 16, 2025 [2][3]. Group 1: Lawsuit Details - The complaint alleges that the defendants engaged in tax fraud and bribery to conceal this fraud, which resulted in an understatement of the legal risks facing the company [3]. - It is claimed that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all relevant times [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to visit the provided link to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders, having ranked in the Top 50 Report for seven consecutive years [5].